The role of mindfulness and drug therapy in the treatment of pain in postherpetic neuralgia

Efficacy and feasibility of mindfulness-based intervention and pregabalin in an integrated approach for the management of neuropathic pain in postherpetic neuralgia:A randomised controlled study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/056397

Enrollment

Registered

2023-08-10

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G00-G99- Diseases of the nervous system

Interventions

Intervention1: Mindfulness and capsule Pregabalin: Subjects in the study the group are taught to follow mindfulness practise which is to be practised for atleast 5 to 10 minutes a day for the study pe

Eligibility

Inclusion criteria

Inclusion criteria: Patients with diagnosis of post herpetic neuralgia with evident hyperalgesia and allodynia Patients with post herpetic neuralgia should have pain for at least 12 weeks after the healing of rash Patients with pain intensity more than or equal to 4/10 Positive cooperation of the patient

Exclusion criteria

Exclusion criteria: Patients with history of neurological interventions for PHN. Evidence of other sources of chronic or acute pain that may confound the diagnosis Patients with recent history of surgery or intake of Pregabalin in the last 4 weeks. Patients with recent history of myocardial infarction, diabetes mellitus,pancreatitis and vasculitis Patients with evidence of renal impairment or history of alcohol consumption. Patients with cognition impairment or substance abuse disorder

Design outcomes

Primary

Measure	Time frame
Proportion of patients with NRS Pain Scores less than 4/10 at the end of 8th week Neuropathic component of pain using NPSI questionnaire at various designated intervalsTimepoint: At the baseline & at the end of 8th week	—

Secondary

Measure	Time frame
Proportion of PHN patients achieving pain relief as Numerical Rating scale â?? Pain scores of less than 4/10 in the two groups at designated intervals. NRS-Sleep score in the two groups at designated intervals. Pain catastrophizing Scale (PCS) score in the two groups at designated intervals. Quality of Life using Short Form-12 in the two groups at designated intervals. Modulation of the mRNA expression of mTORc1 gene & IL-6 gene & the serum protein estimation of IL-6 genes at the pretreatment and at the end of 8th week. Timepoint: At the baseline, first,second,fourth & eighth weeks	—

Measure

Time frame

Proportion of PHN patients achieving pain relief as Numerical Rating scale â?? Pain scores of less than 4/10 in the two groups at designated intervals. NRS-Sleep score in the two groups at designated intervals. Pain catastrophizing Scale (PCS) score in the two groups at designated intervals. Quality of Life using Short Form-12 in the two groups at designated intervals. Modulation of the mRNA expression of mTORc1 gene & IL-6 gene & the serum protein estimation of IL-6 genes at the pretreatment and at the end of 8th week. Timepoint: At the baseline, first,second,fourth & eighth weeks

—

Countries

India

Contacts

Public ContactDr Shilpa Babu

University college of medical sciences and GTB hospital,Delhi-110095

Profashoksaxena2@gmail.com9810431367

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026